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David S PisetskyRecently, one of our fellows hurried into the small room
where I hang out when I attend in the clinic. The room
is painted a bland yellow and is furnished with only an
examining table and a desk with a computer that is the
portal to our electronic medical record. The fellow
looked worried and wanted advice on a physical finding,
its strangeness clearly alarming her.
‘The patient has black spots next to his nails,’ she said
excitedly. ‘What should I do?’
‘Does the patient have rheumatoid arthritis,’ I asked,
looking away from the computer where I was fiddling
with a Disease Activity Score calculator, testing how
various values for the sedimentation rate can influence
proximity to the target.
‘Yes’, she said.‘Is anything else going on? Fever? Malaise?
Neuropathy?’‘No’, she said.‘Probably it’s nothing to worry about then. Those are
nail fold infarcts’, I said calmly, amused that the
fellow had to ask me at all. ‘It’s sometimes called
bland vasculitis’.
The word vasculitis startled the fellow and ratcheted up
the concern in her face. ‘Vasculitis?’ she said, her eyes wid-
ening. ‘Should I admit the man to the hospital? Should I
start steroids?’ The questions came in rapid succession.
‘No’, I said. The particular fellow regularly looks at
me with an expression of skepticism if not
puzzlement, seemingly surprised that the termCorrespondence: david.pisetsky@duke.edu
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‘Let’s go see him’.
The fellow and I then went to see the patient. The
man looked about 60 years old but had the frail appear-
ance of someone who had suffered rheumatoid arthritis
(RA) for many years. For whatever reason, he had missed
out on modern aggressive therapy, the target never hit or
perhaps even aimed at. His fingers were angulated and
there were nodules on top of his knuckles. At the juncture
of a few of his nails, there were black spots that were
slightly textured but not tender. These were definitely the
nail fold infarcts of RA.
With the diagnosis confirmed, I chatted briefly with
the patient, performed a joint examination (calculating a
low Disease Activity Score despite the deformities) and
asked the fellow to come back to my room so that we
could review rheumatoid vasculitis. I wanted to explain to
her the various forms of vessel involvement in RA: leuko-
cytoclastic; polyarteritis-like with mononeuritis multiplex,
digital gangrene and skin ulcers; and nail fold infracts.
To show her the findings, I Googled rheumatoid vas-
culitis and pulled up images whose appearance startled
me. There were black fingers that looked mummified,
large gaping wounds covered with blood and pus, and a
lower extremity with purpuric lesions that looked like
the aftermath of a shotgun blast. Compared with those
menacing lesions, the pictures of the nail fold infarcts
looked benign.
My fellow, like many others today, has cared for tens if
not hundreds of patients with RA. Would any believe
that this disease once regularly produced the devastation
of vasculitis or, for that matter, the dreaded complications
of Felty’s syndrome, amyloidosis or scleritis? Scleritis
could seriously jeopardize the eye, thinning the sclera so
that the vitreous appeared an ominous blue–black and
about to burst out.
As scholars of disease have noted, RA today appears
to be a less severe disease than it was when I started my
career in the 1970s. Then, patients routinely ‘went up inis an Open Access article distributed under the terms of the Creative Commons
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state we called ‘burnt out’. Life expectancy with advanced
RA could approach that of a malignancy but now, in some
studies, patients with RA do as well as the general popula-
tion. While the effectiveness of modern therapy can defin-
itely improve outcomes in RA, the explanation for a
moderate disease course is not fully known although
smoking is down and the microbiome may have shifted,
gaining or losing some species members.
Rightly, remission in RA – not just improvement – is
now the target of therapy and current studies are
addressing not only whether remission is possible – un-
questionably, it is – but whether continued medication
is necessary to maintain that state. These studies (for ex-
ample, the PRIZE, PRESERVE and AVERT trials among
others) concern patients with disease of varying duration
and activity and involve initial treatment with a combin-
ation of methotrexate and a biological (etanercept, a
tumor necrosis factor (TNF) blocker, or abatacept, a T-
cell costimulatory blocker). The results of these studies
are impressive: the rates of remission or low disease
activity with the combination are high; the dose of the
biological can be reduced or eliminated and low disease
activity often maintained; and in some patients treated
with a combination initially, remission can be maintained
following eventual discontinuation of both agents. Even if
the number of patients who go drug free is small, the
results are nevertheless encouraging.
Few studies have addressed the need for sustained
therapy with only classical small molecule disease modify-
ing anti-rheumatic drugs such as methotrexate or sulfa-
salazine, but it is likely that some patients can similarly
reduce or stop these drugs when remission occurs.
Among those with sustained remission under whatever
regimen, the arthritis may be more amenable to therapy –
the window of opportunity opened more widely – because
the immune system has not yet been permanently reconfi-
gured (perhaps by epigenetic modification), a period of
disease modifying anti-rheumatic drug treatment allow-
ing restitution.
While there may be concern about flares at any time
when the intensity of therapy in RA is lowered, data
suggest that reinstitution of therapy can recapture a re-
sponse. There is also the worry that, despite clinical remis-
sion, synovitis persists and grumbles, with the conditions
that eventually lead to complications such as vasculitis not
fully extinguished. Longer term follow-up is necessary to
determine the fate of those patients whose medication has
been reduced or eliminated.
Given these treatment results observed in practice as
well as clinical trials, it may not be surprising that the
frequency of RA vasculitis has been decreasing steadily.
Interestingly, however, TNF blockers – a mainstay of
current therapy contributing to improved outcomes –may themselves be associated with vasculitis. This com-
plication, which can be manifested by leukocytoclastic
vasculitis on skin biopsy, appears quite rare; it is, of
course, always difficult to ascribe the development of a
complication to a therapy rather than the course of
disease. Nevertheless, the improvement of the vasculitis
with cessation of the TNF blocker argues that such lesions
can in fact be manifestations of drug toxicity.
Although the control of disease activity in RA is better
today than in the past, vasculitis is still a problem for
some patients and is likely to persist in health care systems
and parts of the world where access to current therapy
may be limited and disease progresses unchecked. Unfor-
tunately, the improvements observed for RA do not seem
to pertain to the vasculitis itself when it does occur. Even
with our current armamentarium of biological and small
molecule immunosuppressives, rheumatoid vasculitis of
the severe necrotizing variety remains a dire condition
that frequently resists therapy. Along with the occur-
rence of vasculitis that may occur with TNF blockers,
these findings raise questions about the role of cyto-
kines (and other treatment targets) in the vascular
lesion in contrast to the arthritis.
For today’s rheumatologists, the landscape of many rheu-
matologic conditions – RA, ankylosing spondylitis, psori-
atic arthritis – is vastly different from that just a generation
ago. These changes are undoubtedly influenced by modern
approaches to diagnosis and treatment, especially early
aggressive therapy to treat to target with effective agents. I
am glad I have been around to watch this transformation
and, next time my fellow comes into my office to ask me
about a toe that looks like a sausage, I will have my
memory to tell her the meaning of the finding. I will, of
course, have as a help that other great teacher of mod-
ern medicine – Google – to give her an image that she
can remember even if, in regular practice, she never sees
it again.Abbreviations
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